MarketCapExport financials
Varex Imaging Corporation (VREX)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Varex Imaging Corporation Income Statement 2025-2011 | VREX
Brief overview of income trends at Varex Imaging Corporation
The conclusions below are based on five years of reported results. Varex Imaging Corporation reported revenue of 738 million dollars in 2020 and 845 million dollars by 2025. The cumulative result was +14.4%, corresponding to roughly 2.7% per year. The scale of the core business was largely unchanged.
The gross result shifted from $190 million to $290 million, or +52.7%. Revenue outpaced cost of revenue, allowing more sales to flow into gross profit. Gross margin moved from 25.8% to 34.4%. The business retained more gross profit from each unit of revenue.
EBITDA changed from −$11.4 million to −$4.6 million (+59.6%). The operating result outpaced sales and points to improving efficiency. Comparing the endpoints gives EBITDA margins of −1.5% and −0.5%. Operating profitability remained broadly stable.
Comparing the endpoints shows a move from −57.9 million dollars to −70.3 million dollars. Larger losses indicate rising pressure on the business.
Market value was $621 million at the start and $502 million at the end. The decline in value indicates softer investor confidence.
What the figures show
The results contain several connected negative signals. The constructive conclusion rests on consistent operating efficiency and improving gross profitability. Caution is warranted because of lower net income, a softer top-line trend and a low EBITDA margin. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement Varex Imaging Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
502 M | 577 M | 752 M | 889 M | 1.24 B | 621 M | 1.12 B | 947 M | 1.28 B | - | - | - | - | - | - |
Shares |
41.4 M | 40.8 M | 40.3 M | 39.8 M | 39.3 M | 38.8 M | 38.6 M | 38.4 M | 38 M | - | - | - | - | - | - |
Historical Prices |
12.1 | 14.1 | 18.6 | 22.3 | 31.6 | 16.7 | 29.8 | 23.7 | 40.2 | - | - | - | - | - | - |
Net Income |
-70.3 M | -48.8 M | 47.4 M | 30.3 M | 17.4 M | -57.9 M | 15.5 M | 27.5 M | 51.6 M | 68.5 M | 80 M | 110 M | 110 M | - | - |
Revenue |
845 M | 811 M | 893 M | 859 M | 818 M | 738 M | 781 M | 773 M | 698 M | 620 M | 632 M | 685 M | 670 M | - | - |
Cost of Revenue |
554 M | 554 M | 603 M | 576 M | 547 M | 548 M | 524 M | 520 M | 445 M | 372 M | 382 M | - | - | - | - |
Gross Profit |
290 M | 257 M | 290 M | 284 M | 272 M | 190 M | 257 M | 254 M | 254 M | 248 M | 251 M | 279 M | 268 M | - | - |
Operating Income |
-27.8 M | 32.1 M | 77.1 M | 88.2 M | 74.1 M | -33.7 M | 45.7 M | 44.5 M | 83.7 M | 109 M | 128 M | - | - | - | - |
Interest Expense |
-4.4 M | -4.2 M | 29.3 M | 39.8 M | 42.1 M | 31.4 M | 21.1 M | 21.7 M | 12.3 M | 1.9 M | 1.2 M | - | - | - | - |
EBITDA |
-4.6 M | 53.3 M | 96.6 M | 107 M | 94.6 M | -11.4 M | 84.9 M | 86.7 M | 111 M | 124 M | 140 M | 186 M | 179 M | - | - |
Operating Expenses |
318 M | 225 M | 213 M | 195 M | 197 M | 224 M | 211 M | 209 M | 170 M | 139 M | 123 M | 103 M | 99.3 M | - | - |
General and Administrative Expenses |
133 M | 138 M | 128 M | 118 M | 126 M | 142 M | 128 M | 126 M | 102 M | 85.8 M | - | - | - | - | - |
All numbers in USD currency
Quarterly Income Statement Varex Imaging Corporation
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
41.5 M | 42 M | 41.8 M | 41.8 M | 41.7 M | 41.5 M | 41.4 M | 41.1 M | 41.1 M | 40.9 M | 40.7 M | 40.6 M | 40.5 M | 40.4 M | 40.2 M | 40.1 M | 40.1 M | 39.9 M | 39.7 M | 39.5 M | 39.4 M | 39.4 M | 39.2 M | 38.5 M | 38.7 M | 39 M | 38.6 M | - | 38.2 M | 38.3 M | 38.2 M | 38.1 M | 37.8 M | 37.9 M | 38.1 M | 37.7 M | 37.5 M | 37.6 M | 37.7 M | 37.4 M | 37.4 M | 37.4 M | 37.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-89.1 M | -8.1 M | 2.3 M | 2.3 M | - | -89.1 M | 6.9 M | -300 K | - | 1.4 M | 1.4 M | -500 K | - | 9.1 M | 4.1 M | 3.1 M | - | 8.2 M | 7.6 M | 1.4 M | - | 12 M | 3.1 M | -1.3 M | -31.5 M | -28.3 M | -1.9 M | - | 7.4 M | -1.4 M | 5.8 M | 3 M | 27.5 M | 3.8 M | 3 M | 11.3 M | 36.8 M | 10.6 M | 11.3 M | 11.1 M | 46.5 M | 17.6 M | 11.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
203 M | 216 M | 210 M | 210 M | - | 203 M | 213 M | 200 M | - | 209 M | 206 M | 190 M | - | 232 M | 228 M | 206 M | - | 214 M | 215 M | 199 M | - | 211 M | 204 M | 200 M | 568 M | 171 M | 197 M | - | 578 M | 197 M | 196 M | 186 M | 569 M | 191 M | 201 M | 176 M | 482 M | 170 M | 155 M | 157 M | 448 M | 151 M | 157 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
136 M | 143 M | 140 M | 140 M | - | 136 M | 136 M | 131 M | - | 142 M | 140 M | 133 M | - | 156 M | 156 M | 142 M | - | 141 M | 144 M | 134 M | - | 137 M | 139 M | 139 M | 423 M | 145 M | 139 M | - | 393 M | 136 M | 131 M | 126 M | 374 M | 128 M | 131 M | 115 M | 307 M | 111 M | 97.2 M | 98.6 M | 269 M | 88.4 M | 98.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
67.5 M | 72.6 M | 69.8 M | 69.8 M | - | 67.5 M | 76.7 M | 68.5 M | - | 66.9 M | 65.8 M | 57.1 M | - | 76.3 M | 72.7 M | 63.3 M | - | 73.4 M | 70.8 M | 64.8 M | - | 74.1 M | 64.6 M | 61.1 M | 145 M | 26.3 M | 57.6 M | - | 185 M | 60.7 M | 64.4 M | 60 M | 195 M | 63 M | 60 M | 61.5 M | 176 M | 59.5 M | 61.5 M | 58.8 M | 179 M | 63 M | 58.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-80.7 M | 14.4 M | 15.4 M | 15.4 M | - | -80.7 M | 22.1 M | 11.2 M | - | 9.3 M | 7.7 M | 4.2 M | - | 24.2 M | 15.6 M | 13 M | - | 23 M | 26.6 M | 14 M | - | 25.7 M | 15.8 M | 4.6 M | -20.8 M | -26.8 M | 1.4 M | - | 29.5 M | 4.6 M | 14.5 M | 10.4 M | 38.1 M | 7.3 M | 10.4 M | 13.6 M | 57.1 M | 15.5 M | 13.6 M | 18.6 M | 76.1 M | 28.4 M | 18.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
1 M | -4 M | -4.3 M | -4.3 M | - | 1 M | -4 M | -2.8 M | - | -2.9 M | 700 K | 600 K | - | -700 K | 7.3 M | 7.5 M | - | 9.4 M | 11.1 M | 9.9 M | - | 10.6 M | 10.4 M | 5.4 M | 16.9 M | 6.9 M | 4.6 M | - | 15.7 M | 5.1 M | 5.5 M | 5.1 M | 16.5 M | 5.4 M | 5.1 M | 5.5 M | 5.8 M | 4.2 M | 5.5 M | 600 K | 1.3 M | 400 K | 600 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-79.7 M | 25.8 M | 21.1 M | 21.1 M | - | -79.7 M | 23.1 M | 17.4 M | - | 11 M | 11.3 M | 9.3 M | - | 27.6 M | 19 M | 17.6 M | - | 26.7 M | 30.3 M | 18.8 M | - | 36.2 M | 20.1 M | 9.8 M | -3.5 M | -15.4 M | 5.8 M | - | 48.2 M | 18.7 M | 18.1 M | 20.2 M | 54.1 M | 17.8 M | 20.2 M | 18.5 M | 67.7 M | 24 M | 18.5 M | 21.7 M | 83.3 M | 32.8 M | 21.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
148 M | 58.2 M | 54.4 M | 54.4 M | - | 148 M | 54.6 M | 57.3 M | - | 57.6 M | 58.1 M | 52.9 M | - | 52.1 M | 57.1 M | 50.3 M | - | 50.4 M | 44.2 M | 50.8 M | - | 48.4 M | 48.8 M | 56.5 M | 166 M | 53.1 M | 56.2 M | - | 156 M | 56.1 M | 49.9 M | 49.6 M | 157 M | 55.7 M | 49.6 M | 47.9 M | 119 M | 44 M | 47.9 M | 40.2 M | 103 M | 34.6 M | 40.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
32.9 M | 36 M | 32.7 M | 32.7 M | - | 32.9 M | 32.6 M | 33.8 M | - | 35.6 M | 35.5 M | 32.4 M | - | 32.1 M | 34.1 M | 30.3 M | - | 30.2 M | 25.3 M | 33.1 M | - | 29.2 M | 30.6 M | 34.8 M | 102 M | 31.4 M | 35.3 M | - | 92.3 M | 31.2 M | 30.3 M | 30.8 M | 94.3 M | 35.2 M | 30.8 M | 28.2 M | 73.3 M | 26.3 M | 28.2 M | 26.9 M | 63.5 M | 20.6 M | 26.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Varex Imaging Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical devices industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Conformis
CFMS
|
- | - | $ 16.4 M |  USA |
 |
Boston Scientific Corporation
BSX
|
$ 43.92 | 0.06 % | $ 65 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
$ 8.52 | 0.06 % | $ 621 M |  Israel |
 |
ClearPoint Neuro
CLPT
|
$ 14.83 | 1.51 % | $ 420 M | USA |
 |
CONMED Corporation
CNMD
|
$ 45.38 | 0.44 % | $ 1.41 B | USA |
 |
Cytosorbents Corporation
CTSO
|
$ 4.38 | 1.86 % | $ 273 M | USA |
 |
Delcath Systems
DCTH
|
$ 15.6 | 0.75 % | $ 559 M | USA |
 |
Eargo
EAR
|
- | - | $ 10.2 M | USA |
 |
Medigus Ltd.
MDGS
|
- | 10.28 % | $ 55.5 M | Israel |
 |
Electromed
ELMD
|
$ 27.88 | 0.07 % | $ 230 M | USA |
 |
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | USA |
 |
Establishment Labs Holdings
ESTA
|
$ 65.97 | 0.59 % | $ 1.95 B |  Costa-rica |
 |
Edwards Lifesciences Corporation
EW
|
$ 86.29 | 0.66 % | $ 50.5 B | USA |
 |
Nemaura Medical
NMRD
|
- | -17.8 % | $ 2.74 M |  Britain |
 |
Helius Medical Technologies
HSDT
|
$ 2.94 | 1.38 % | $ 64.8 M | USA |
 |
AdaptHealth Corp.
AHCO
|
$ 5.64 | 1.26 % | $ 762 M | USA |
 |
Inogen
INGN
|
$ 5.36 | 2.49 % | $ 143 M | USA |
 |
InMode Ltd.
INMD
|
$ 14.26 | 0.49 % | $ 922 M | Israel |
 |
Inspire Medical Systems
INSP
|
$ 70.5 | 2.46 % | $ 2.07 B | USA |
 |
IRIDEX Corporation
IRIX
|
$ 0.63 | 0.16 % | $ 10.7 M | USA |
 |
IRadimed Corporation
IRMD
|
$ 85.76 | 0.66 % | $ 1.09 B | USA |
 |
Neovasc
NVCN
|
- | - | $ 111 M |  Canada |
 |
AxoGen
AXGN
|
$ 43.39 | 0.16 % | $ 2 B | USA |
 |
Align Technology
ALGN
|
$ 146.78 | 0.79 % | $ 10.6 B | USA |
|
LENSAR
LNSR
|
$ 6.92 | 0.28 % | $ 82.7 M | USA |
 |
Sientra
SIEN
|
- | -16.59 % | $ 10.3 M | USA |
 |
Silk Road Medical, Inc
SILK
|
- | - | $ 1.07 B | USA |
 |
Medtronic PLC
MDT
|
$ 88.64 | 0.98 % | $ 114 B | USA |
 |
MiMedx Group
MDXG
|
$ 4.67 | 0.1 % | $ 690 M | USA |
 |
Surgalign Holdings
SRGA
|
- | -32.98 % | $ 1.68 M | USA |
 |
ShockWave Medical
SWAV
|
- | - | $ 12.3 B | USA |
 |
Myomo
MYO
|
$ 1.61 | 0.6 % | $ 67.4 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
$ 0.64 | 0.02 % | $ 41.5 M | Israel |
 |
InspireMD
NSPR
|
$ 0.7 | 0.71 % | $ 45 M | Israel |
 |
Orthofix Medical
OFIX
|
$ 9.44 | 3.06 % | $ 374 M |  Curacao |
 |
Outset Medical
OM
|
$ 3.05 | 1.29 % | $ 46.4 K | USA |
 |
Insulet Corporation
PODD
|
$ 136.13 | 0.26 % | $ 9.58 B | USA |
 |
Quanterix Corporation
QTRX
|
$ 3.27 | 2.83 % | $ 139 M | USA |
 |
Titan Medical
TMDI
|
- | -26.32 % | $ 19.6 M | Canada |
 |
AVITA Medical
RCEL
|
$ 11.84 | 2.25 % | $ 330 M |  Australia |
 |
Natus Medical Incorporated
NTUS
|
- | 1.94 % | $ 1.05 B | USA |
 |
Cardiovascular Systems
CSII
|
- | 0.15 % | $ 844 M | USA |
 |
Apyx Medical Corporation
APYX
|
$ 2.96 | 4.59 % | $ 122 M | USA |
 |
Sintx Technologies
SINT
|
$ 1.88 | 0.53 % | $ 5.21 M | USA |
 |
Smith & Nephew plc
SNN
|
$ 26.91 | 0.86 % | $ 23.3 B | Britain |
 |
Accuray Incorporated
ARAY
|
$ 0.22 | 1.84 % | $ 27 M | USA |
 |
Inari Medical
NARI
|
- | - | $ 4.23 B | USA |
 |
Sensus Healthcare
SRTS
|
$ 2.94 | 1.03 % | $ 48 M | USA |
 |
Bruker Corporation
BRKR
|
$ 64.18 | 0.28 % | $ 9.74 B | USA |
 |
Stryker Corporation
SYK
|
$ 272.36 | 0.97 % | $ 104 B | USA |